Extreme Nonfasting Remnant Cholesterol vs Extreme LDL Cholesterol as Contributors to Cardiovascular Disease and All-Cause Mortality in 90000 Individuals from the General Population

被引:153
作者
Varbo, Anette [1 ,2 ,4 ]
Freiberg, Jacob J. [1 ,2 ,4 ]
Nordestgaard, Borge G. [1 ,2 ,3 ,4 ]
机构
[1] Copenhagen Univ Hosp, Herlev Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark
[2] Copenhagen Univ Hosp, Herlev Hosp, Copenhagen Gen Populat Study, DK-2730 Herlev, Denmark
[3] Copenhagen Univ Hosp, Frederiksberg Hosp, Copenhagen City Heart Study, Frederiksberg, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark
关键词
ISCHEMIC-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY-DISEASE; HIGH-RISK PATIENTS; SECONDARY PREVENTION; MYOCARDIAL-INFARCTION; HDL CHOLESTEROL; FOLLOW-UP; IN-VIVO; TRIGLYCERIDES;
D O I
10.1373/clinchem.2014.234146
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACKGROUND: Increased nonfasting remnant cholesterol, like increased LDL cholesterol, is causally associated with increased risk for ischemic heart disease (IHD). We tested the hypothesis that extreme concentrations of nonfasting remnant and LDL cholesterol are equal contributors to the risk of IHD, myocardial infarction (MI), and all-cause mortality. METHODS: We compared stepwise increasing concentrations of nonfasting remnant and LDL cholesterol for association with risk of IHD, MI, and all-cause mortality in approximately 90000 individuals from the Danish general population. During up to 22 years of complete follow-up, 4435 participants developed IHD, 1722 developed MI, and 8121 died. RESULTS: Compared with participants with nonfasting remnant cholesterol <0.5 mmol/L (19.3 mg/dL), hazard ratios for IHD ranged from 1.3 (95% CI 1.1-1.5) for remnant cholesterol of 0.5-0.99 mmol/L (19.3-38.2 mg/dL) to 2.4 (1.9-2.9) for remnant cholesterol of >= 1.5 mmol/L (58 mg/dL) (P for trend <0.001). Compared with participants with LDL cholesterol <3.0 mmol/L (115.8 mg/dL), hazard ratios for IHD ranged from 1.3 (1.1-1.5) for LDL cholesterol of 3-3.99 mmol/L (115.8-154 mg/dL) to 2.3 (1.9-2.8) for LDL cholesterol of >= 5 mmol/L (193 mg/dL) (P < 0.001). Corresponding hazard ratios for MI ranged from 1.8 (1.4-2.3) to 3.4 (2.5-4.8) for remnant cholesterol (P < 0.001), and from 1.7 (1.4-2.2) to 4.7 (3.5-6.3) for LDL cholesterol (P < 0.001). Nonfasting remnant cholesterol concentrations were associated stepwise with all-cause mortality ranging from hazard ratio 1.0 (0.9-1.1) to 1.6 (1.4-1.9) (P < 0.001), whereas LDL cholesterol concentrations were associated with decreased all-cause mortality risk in a U-shaped pattern, with hazard ratios from 0.8 (0.7-0.8) to 0.9 (0.8-1.0) (P = 0.002). After mutual adjustment, LDL cholesterol best predicted MI, and remnant cholesterol best predicted all-cause mortality. CONCLUSIONS: Both lipoproteins were associated equally with risk of IHD and MI; however, only nonfasting remnant cholesterol concentrations were associated stepwise with increased all-cause mortality risk. (C) 2015 American Association for Clinical Chemistry
引用
收藏
页码:533 / 543
页数:11
相关论文
共 34 条
[1]  
[Anonymous], CLINICALTRIALS
[2]   Effects of torcetrapib in patients at high risk for coronary events [J].
Barter, Philip J. ;
Caulfield, Mark ;
Eriksson, Mats ;
Grundy, Scott M. ;
Kastelein, John J. P. ;
Komajda, Michel ;
Lopez-Sendon, Jose ;
Mosca, Lori ;
Tardif, Jean-Claude ;
Waters, David D. ;
Shear, Charles L. ;
Revkin, James H. ;
Buhr, Kevin A. ;
Fisher, Marian R. ;
Tall, Alan R. ;
Brewer, Bryan .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122
[3]   Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study [J].
Benn, Marianne ;
Tybjaerg-Hansen, Anne ;
Stender, Stefan ;
Frikke-Schmidt, Ruth ;
Nordestgaard, Borge G. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (06) :508-519
[4]   Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].
Boden, William E. ;
Probstfield, Jeffrey L. ;
Anderson, Todd ;
Chaitman, Bernard R. ;
Desvignes-Nickens, Patrice ;
Koprowicz, Kent ;
McBride, Ruth ;
Teo, Koon ;
Weintraub, William .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267
[5]  
CARLSON LA, 1988, ACTA MED SCAND, V223, P405
[6]   Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management [J].
Chapman, M. John ;
Ginsberg, Henry N. ;
Amarenco, Pierre ;
Andreotti, Felicita ;
Boren, Jan ;
Catapano, Alberico L. ;
Descamps, Olivier S. ;
Fisher, Edward ;
Kovanen, Petri T. ;
Kuivenhoven, Jan Albert ;
Lesnik, Philippe ;
Masana, Luis ;
Nordestgaard, Borge G. ;
Ray, Kausik K. ;
Reiner, Zeljko ;
Taskinen, Marja-Riitta ;
Tokgozoglu, Lale ;
Tybjaerg-Hansen, Anne ;
Watts, Gerald F. .
EUROPEAN HEART JOURNAL, 2011, 32 (11) :1345-1361
[7]  
Clarke R, 1999, AM J EPIDEMIOL, V150, P341
[8]   Common variants associated with plasma triglycerides and risk for coronary artery disease [J].
Do, Ron ;
Willer, Cristen J. ;
Schmidt, Ellen M. ;
Sengupta, Sebanti ;
Gao, Chi ;
Peloso, Gina M. ;
Gustafsson, Stefan ;
Kanoni, Stavroula ;
Ganna, Andrea ;
Chen, Jin ;
Buchkovich, Martin L. ;
Mora, Samia ;
Beckmann, Jacques S. ;
Bragg-Gresham, Jennifer L. ;
Chang, Hsing-Yi ;
Demirkan, Ayse ;
Den Hertog, Heleen M. ;
Donnelly, Louise A. ;
Ehret, Georg B. ;
Esko, Tonu ;
Feitosa, Mary F. ;
Ferreira, Teresa ;
Fischer, Krista ;
Fontanillas, Pierre ;
Fraser, Ross M. ;
Freitag, Daniel F. ;
Gurdasani, Deepti ;
Heikkila, Kauko ;
Hyppoenen, Elina ;
Isaacs, Aaron ;
Jackson, Anne U. ;
Johansson, Asa ;
Johnson, Toby ;
Kaakinen, Marika ;
Kettunen, Johannes ;
Kleber, Marcus E. ;
Li, Xiaohui ;
Luan, Jian'an ;
Lyytikainen, Leo-Pekka ;
Magnusson, Patrik K. E. ;
Mangino, Massimo ;
Mihailov, Evelin ;
Montasser, May E. ;
Mueller-Nurasyid, Martina ;
Nolte, Ilja M. ;
O'Connell, Jeffrey R. ;
Palmer, Cameron D. ;
Perola, Markus ;
Petersen, Ann-Kristin ;
Sanna, Serena .
NATURE GENETICS, 2013, 45 (11) :1345-+
[9]  
Freiberg JJ, 2008, JAMA-J AM MED ASSOC, V300, P2142, DOI [10.1001/jama.2008.621, 10.1002/ana.22384]
[10]  
Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282